SCHD Annual Reconstitution: Here's What This Dividend ETF Looks Like Now

The Schwab U.S. Dividend Equity ETF completed its annual reconstitution: 22 stocks removed, 25 added, and three new top-10 holdings (Abbott Laboratories and UnitedHealth Group joined the fund and top 10; Chevron is now the largest holding at ~4.6%, ConocoPhillips ~4.2%). Sector changes are modest: Communication Services +2.8pp to 7.1%, Technology +2.8pp to 11.0%, Healthcare +2.4pp to 18.6%, Energy -3.4pp to 16.5%, and Materials down 2.7pp to 0%; the author notes portfolio quality and durability are unchanged, implying limited change to ETF performance. Expect modest stock-level flows and potential 1–3% moves in affected names but no material shift to the fund's risk/return profile.

Analysis

The reconstitution subtly tilts durable-capital into large-cap healthcare and high-quality tech dividends while trimming raw cyclicals; that micro-shift will mechanically bid up high-liquidity names (UNH/ABT/AMGN/TXN) over the next 3–8 trading days as index-tracking flows complete, and sustain outperformance versus smaller dividend names over 3–12 months if dividend visibility stays intact. Forced ETF selling on names that lost eligibility (ABBV/CSCO/HAL/VLO) creates a predictable short-run liquidity shock: expect 2–6% incremental downside volatility in those tickers over 1–3 weeks versus their pre-rebalance baselines, especially where buyback yields are weaker.

Second-order winners include dividend-sensitive semis and payment-adjacent vendors (TXN, QCOM, ADP) that benefit from rotation into higher-margin, capital-light businesses — this increases earnings multiple support even with modest yield compression; conversely, commodity capex-heavy energy services and refiners face lower passive demand and a higher cost-of-capital tailwind to underperformance if oil reverses. Key catalysts to monitor are (1) dividend guidance from newly added names over the next 2 quarters, (2) any outsized ETF liquidation prints in the first 10 days post-rebalance, and (3) sector moves in energy/tech that can flip relative performance in 3–6 months. Tail risks: dividend cuts, a sudden spike in rates that reprices defensive multiples, or a broader liquidity event that exaggerates index reweighting impacts and reverses the tactical healthcare bid.

Key Decisions for Investors

• Buy ABT and UNH (2–4% portfolio each) over the next 5 trading days to capture reconstitution-led bid; target 8–15% upside in 3–9 months if earnings/dividend guidance remains stable; place initial stop-loss at -6% to limit execution/flow risk.
• Short ABBV and CSCO tactically (1–2% portfolio each) for 1–4 week trades to monetize forced selling, targeting 4–8% downside; cut loss at +5% if outflows dissipate or buyback announcements arrive.
• Long TXN and QCOM on pullbacks (scale in over 10 trading days, 1.5% each) to play the tilt toward dividend-paying tech; hold 6–12 months, target 10–20% relative outperformance vs regional peers; stop -8%.
• Options replacement: buy 12–18 month calls on ABT/UNH (size ~0.5–1% of portfolio per position) instead of full equity exposure to cap downside while keeping upside; close or hedge if implied vols spike >25% above 30-day average.
• Monitor SCHD-related flows: set alerts for >$100–200mm prints in top-20 names (execution window 0–10 days); if observed, use liquidity spikes to scale into long positions in added names and to initiate shorts in names with persistent outflows.